Ursula Scheffel of Johns Hopkins University describes the development of PET and SPECT radioligands targeting the serotonin transporter. The description details the need for such imaging agents to screen at-risk populations and study serotonergic function in neuropsychiatric disorders. It evaluates several candidate tracers, including [11C]RTI-55 and [11C]McN-5652-X, discussing their binding affinity, selectivity, and current research status.
Use Cases
- Evaluating radioligand binding affinity and selectivity for serotonin uptake sites based on described candidate compounds.
- Screening human populations at risk for serotonergic dysfunction based on exposure to neurotoxic amphetamines mentioned in the description.
- Studying altered serotonergic neurotransmission in diseases like depression and obsessive-compulsive disorder using the described imaging agents.
- Comparing target-to-nontarget ratios of PET tracers like [11C]fluoxetine and [11C]citalopram as detailed in the text.
Strengths
- Description provides specific evaluation metrics for candidate tracers, such as target-to-nontarget ratios less than 2.0:1 over 90 minutes.
- Identifies promising agents like [11C]McN-5652-X, noted for its high selectivity for 5-HT uptake sites.
- Discusses methodological possibilities, such as using stereoisomer subtraction to determine regional-specific binding.
Limitations
- Row count is unknown, which may limit suitability assessment.
- Column-level documentation is absent; field semantics must be inferred after download.
- Last update date is unknown; freshness unverified.
Provenance
- Source
- Ursula Scheffel, Johns Hopkins University, via paperswithcode
- Collection Method
- Likely a literature review or research summary on radioligand development.